Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
10/2003
10/16/2003US20030195164 Novel ribozyme and its use
10/16/2003US20030195163 Fibronectins; drug screening; treating cardiovascular/nervous system disorders
10/16/2003US20030195159 HIV protease inhibitors based on amino acid derivatives
10/16/2003US20030195158 Peptide derivatives
10/16/2003US20030195157 Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
10/16/2003US20030195156 Tumor necrosis factors; cytokines; immunoglobulins; autoimmune diseases
10/16/2003US20030195155 Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives
10/16/2003US20030195154 Comprises mimetics of erythropoietin, thrombopoietin, and glucagon-like peptide conjugated to polymer
10/16/2003US20030195153 Comprises metalloproteinase (stromelysin) inhibitors
10/16/2003US20030195150 Antimicrobial peptides
10/16/2003US20030195149 Endozepine-like proteins, polynucleotides encoding them and methods of using the same
10/16/2003US20030195148 Secreted and transmembrane polypeptides and nucleic acids encoding the same
10/16/2003US20030195147 Identification of molecular structures, especially peptides, which are capable of acting at either insulin or insulin-like growth factor receptors as agonists or antagonists; treatment of diabetes
10/16/2003US20030195146 Prepared by culturing Beauveria in medium; substances thus obtained are less toxic, specifically inhibit acyl-Coenzyme A: cholesterol acyltransferase, and inhibit formation of oil droplets in macrophages
10/16/2003US20030195145 Methods of treatment with combinations of statin and aryl-substituted propanolamine derivatives
10/16/2003US20030195144 Antimicrobial compounds and formulations
10/16/2003US20030195143 Medicament containing a tissue inhibitor of metalloproteinases-2 (timp-2) as an osteoanabolically active substance
10/16/2003US20030195142 Formulated composition
10/16/2003US20030195141 Anti-inflammatory peptides
10/16/2003US20030195138 BAP-1: methods of assaying for cell-cycle modulators
10/16/2003US20030194800 For immunization, generation of packaging cell lines, and production of immunogenic compositions
10/16/2003US20030194797 Metalloproteinase ADAM 22
10/16/2003US20030194794 Secreted and transmembrane polypeptides and nucleic acids encoding the same
10/16/2003US20030194793 Used as pharmaceuticals, diagnostics, biosensors and bioreactors
10/16/2003US20030194792 Used as pharmaceuticals, diagnostics, biosensors and bioreactors
10/16/2003US20030194791 Used as pharmaceuticals, diagnostics, biosensors and bioreactors
10/16/2003US20030194783 Co-administration of interleukin-3 mutant polypeptides with CSF's for multi-lineage hematopoietic cell production
10/16/2003US20030194779 Used as pharmaceuticals, diagnostics, biosensors and bioreactors
10/16/2003US20030194778 Used as pharmaceuticals, diagnostics, biosensors and bioreactors
10/16/2003US20030194777 Secreted and transmembrane polypeptides and nucleic acids encoding the same
10/16/2003US20030194776 Secreted and transmembrane polypeptides and nucleic acids encoding the same
10/16/2003US20030194775 Used as pharmaceuticals, diagnostics, biosensors and bioreactors
10/16/2003US20030194774 Secreted and transmembrane polypeptides and nucleic acids encoding the same
10/16/2003US20030194773 Secreted and transmembrane polypeptides and nucleic acids encoding the same
10/16/2003US20030194772 Secreted and transmembrane polypeptides and nucleic acids encoding the same
10/16/2003US20030194771 Secreted and transmembrane polypeptides and nucleic acids encoding the same
10/16/2003US20030194770 Secreted and transmembrane polypeptides and nucleic acids encoding the same
10/16/2003US20030194769 Secreted and transmembrane polypeptides and nucleic acids encoding the same
10/16/2003US20030194768 Secreted and transmembrane polypeptides and nucleic acids encoding the same
10/16/2003US20030194767 Used as pharmaceuticals, diagnostics, biosensors and bioreactors
10/16/2003US20030194766 Used as pharmaceuticals, diagnostics, biosensors and bioreactors
10/16/2003US20030194765 Secreted and transmembrane polypeptides and nucleic acids encoding the same
10/16/2003US20030194761 Novel nucleic acid sequences encoding human fibroblast growth factor-like polypeptides
10/16/2003US20030194760 Secreted and transmembrane polypeptides and nucleic acids encoding the same
10/16/2003US20030194744 Secreted and transmembrane polypeptides and nucleic acids encoding the same
10/16/2003US20030194743 Binding polypeptides for B lymphocyte stimulator protein (BLyS)
10/16/2003US20030194742 Diagnosis of tauopathies
10/16/2003US20030194739 Using cancer specific genes
10/16/2003US20030194738 Antisense oligonucletoide to c-Fos; used to control cell proliferation and treat tumors; oligonucleotides with modified linkages, nucleobases, and sugar groups; pharmaceutical mixture with chemotherapeutic agents
10/16/2003US20030194737 Use of parapox B2L protein to modify immune responses to administered antigens
10/16/2003US20030194732 For treating neoplastic diseases by testing responsiveness to interferons
10/16/2003US20030194729 Conantokins
10/16/2003US20030194725 Creating a database of related protein/nucleic acid sequences with annotations of the potential disease associations of the sequences; testing the potential disease associations by means of a biological assay and validating the disease association
10/16/2003US20030194720 Human ion channels
10/16/2003US20030194708 Human secreted crossveinless-homolog polypeptide
10/16/2003US20030194695 Nucleic acid and polypeptide sequences useful as adjuvants
10/16/2003US20030194453 Dietary supplement
10/16/2003US20030194414 Replikin peptides and antibodies therefore
10/16/2003US20030194408 Antibody which specifically binds to at least two variants of an epitope of an HIV-1 Tat protein
10/16/2003US20030194402 Methods of sustained treatment of fistulas in crohn's disease with chimeric anti-TNF antibodies
10/16/2003US20030194401 Agent that interacts with MHC beta2-microglobulin HLA class 1 molecules located on the tumor cell surface
10/16/2003US20030194400 Targeted thrombosis
10/16/2003US20030194398 Having serine protease inhibitory activity
10/16/2003US20030194397 Introducing platelet-rich plasma into and around the site of the injury
10/16/2003US20030194396 Antisense oligonucleotide that hybridizes iwth and inhibits the expression of human pituitary tumor-transforming gene
10/16/2003US20030194391 Vaccine
10/16/2003US20030194377 Therapeutic uses of BPI protein products in cystic fibrosis patients
10/16/2003US20030192555 Direct arterial infiltration for production of vascular pathology
10/16/2003US20030192540 Therapeutic dry powder preparation
10/16/2003CA2513149A1 A human ribonucleotide reductase m2 subunit
10/16/2003CA2509767A1 Novel antagonists of mcp proteins
10/16/2003CA2481970A1 Neurotrophic factor production accelerator
10/16/2003CA2481829A1 Anti-idiotype anti-cea antibody molecules and its use as cancer vaccine
10/16/2003CA2481466A1 Depsipeptide for therapy of kidney cancer
10/16/2003CA2481090A1 Novel pancortin-pablo protein interactions and methods of use thereof
10/16/2003CA2481039A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
10/16/2003CA2480996A1 Peptides derived or obtained from cytokine and the application thereof in therapy
10/16/2003CA2480790A1 Use of antithrombin iii in treating acute lung injury
10/16/2003CA2480709A1 Method of improving absorption of vitamin e by a pet animal
10/16/2003CA2480692A1 Chemokines mutants having improved oral bioavailability
10/16/2003CA2480598A1 Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between cd28 and the superantigen and uses thereof
10/16/2003CA2480505A1 Use of botulinum toxin for treating cardiovasular diseases
10/16/2003CA2480450A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
10/16/2003CA2480446A1 Method and dietary composition for improving lipid digestibility
10/16/2003CA2480311A1 Oligomeric compounds for the modulation of hif-1alpha expression
10/16/2003CA2480084A1 Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis
10/16/2003CA2478227A1 Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist
10/16/2003CA2477943A1 Heterocyclic amides with alpha-4 integrin antagonist activity
10/16/2003CA2453020A1 Use of long pentraxin ptx3 for the treatment of fgf-8 mediated tumour diseases
10/15/2003EP1352962A1 186 human secreted proteins
10/15/2003EP1352961A1 Synovial cell protein
10/15/2003EP1352956A1 Inhibition of DNA methyltransferase
10/15/2003EP1352912A1 Parathyroid hormone analogues for the treatment of osteoporosis
10/15/2003EP1352911A1 Angiotensin converting enzyme inhibitors
10/15/2003EP1352657A1 Interferon therapeutic effect-potentiating agents
10/15/2003EP1352656A2 Combination therapy using a TNF binding protein for treating TNF-mediated diseases
10/15/2003EP1352651A2 Novel use of orexin receptor antagonists
10/15/2003EP1352240A2 Cloning and expression of a new mcp receptor in glial cells
10/15/2003EP1352092A2 Mutations in the ferroportin 1 gene associated with hereditary haemochromatosis
10/15/2003EP1352091A2 Compositions and methods enabling a totally internally controlled amplification reaction
1 ... 1751 1752 1753 1754 1755 1756 1757 1758 1759 1760 1761 1762 1763 1764 1765 1766 1767 1768 1769 1770 1771 ... 3163